Peptide profile · Weight Management
Pramlintide
Synthetic amylin analog for comprehensive postprandial glucose control with insulin therapy
Written & reviewed by Michael Carroll · Research, Peptide Initiative
Typical dose
30-60 mcg per meal (type 1 diabetes)
Half-life
~48 minutes
Bioavailability
30-40% subcutaneous bioavailability
Molecular weight
3,949 Da
Evidence level
Strong human trials
01 · Compound profile
Scientific & efficacy data
Molecular formula
C171H267N51O53S2
Primary benefits
Powerful postprandial glucose regulation through glucagon suppression, gastric emptying delay, and satiety — addressing the amylin deficiency component of diabetes
Clinically meaningful weight loss of 1-2 kg through centrally mediated satiety, particularly beneficial for insulin-treated patients who typically gain weight
Restores the amylin arm of glucose homeostasis that is lost in insulin-dependent diabetes, enabling more physiological glucose regulation
Amylin Pharmaceuticals / AstraZeneca
Amino acid sequence
KCNTATCATQRLANFLVHSSNNFGAILSSTNVGSNTY02 · Dosing
How much do I take?
30-60 mcg per meal (type 1 diabetes) · immediately before each major meal
Subcutaneous: A small injection into the fatty layer just under the skin — the same way insulin is given.
Bioavailability High — most of the dose reaches your bloodstream, just more gradually than an IV.
Best time to take
Administer Pramlintide at the same time each day (or on the same day each week for weekly injections). Many users prefer morning or evening administration. Pick a time you'll remember consistently.
With food?
Pramlintide injections can be given regardless of meal timing. However, if GI effects occur, administering on an empty stomach or with a light meal may help reduce discomfort.
If stacking
Pramlintide should be used as directed by your healthcare provider. If combining with other medications or supplements, discuss potential interactions with your provider. Avoid combining with compounds that have overlapping mechanisms unless specifically guided by a medical professional.
＋ Increase if
- +You've tolerated the current dose for the recommended period without significant side effects
- +Therapeutic goals haven't been met at the current dose level
- +Your healthcare provider recommends dose escalation based on your response
- +Lab work or clinical assessments support a higher dose
－ Decrease if
- −Side effects are bothersome or impacting daily life despite management strategies
- −You experience any signs of an adverse reaction
- −Lab results indicate the need for dose reduction
- −Your healthcare provider recommends a lower dose based on your response
✓ Signs of right dose
- ✓Therapeutic goals being met with minimal side effects
- ✓Stable and consistent response to treatment
- ✓Lab values or clinical markers trending in the right direction
- ✓Good tolerance with manageable or absent side effects
Dosing Calculator
Calculate Your Exact Dose
Step 1: Peptide Weight
Find the weight printed on your peptide vial label
Look here!
The peptide weight is printed on the label
Look here!
The weight is on the label
Select Weight
Look for a number followed by 'mg' on the vial label (e.g., 5mg, 10mg)
03 · Suitability
Is this right for me?
Best for improving postprandial glucose control in insulin-treated diabetes & reducing insulin dose requirements while maintaining glycemic control
Best for
Improving postprandial glucose control in insulin-treated diabetes
Pramlintide is particularly well-suited for individuals focused on improving postprandial glucose control in insulin-treated diabetes. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach.
Reducing insulin dose requirements while maintaining glycemic control
Pramlintide is particularly well-suited for individuals focused on reducing insulin dose requirements while maintaining glycemic control. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach.
Supporting weight management in insulin-treated T1DM and T2DM patients
Pramlintide is particularly well-suited for individuals focused on supporting weight management in insulin-treated t1dm and t2dm patients. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach.
Addressing amylin deficiency in insulin-dependent diabetes
Pramlintide is particularly well-suited for individuals focused on addressing amylin deficiency in insulin-dependent diabetes. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach.
Consider alternatives if
Do not use if
Use with caution if
Not sure?
Compare Pramlintide with similar peptides to find the best fit for your goals.
04 · Administration
How do I use it?
subcutaneous injection
Reconstitution — what you need
Example
Add the recommended volume of bacteriostatic water to the Pramlintide vial. Gently swirl (do not shake) until the powder is fully dissolved. The resulting solution should be clear. Calculate your individual dose based on the concentration and your prescribed amount.
Your dose of Pramlintide is determined by your healthcare provider. Using an insulin syringe marked in units, draw up the exact amount prescribed. For example, if the reconstituted concentration is 1mg/mL and your dose is 0.5mg, draw up 0.5mL (50 units on an insulin syringe). Always double-check calculations before injection.
Route
Subcutaneous injection (into the fatty tissue just under the skin)—allows for consistent absorption and can be self-administered at home after proper training
Best sites
Technique
- 01Wash your hands thoroughly with soap and water before handling supplies
- 02Clean the injection site with an alcohol swab and let it air dry completely
- 03Pinch a fold of skin at the chosen injection site
- 04Insert the needle at a 45-90 degree angle (depending on needle length and body composition)
- 05Inject the medication slowly and steadily over 5-10 seconds
- 06Release the skin fold and remove the needle, applying gentle pressure with a clean swab
- 07Rotate injection sites to prevent tissue irritation or lipodystrophy
- 08Dispose of the needle safely in a sharps container—never recap or reuse needles
Storage · before reconstitution
Store Pramlintide in the refrigerator at 36-46°F (2-8°C) in its original packaging. Protect from light and moisture. Do not freeze. Check the expiration date before use. Some formulations may be stored at room temperature for limited periods—check your specific product labeling.
Storage · after reconstitution
Once reconstituted, Pramlintide should be kept refrigerated at 36-46°F (2-8°C) and used within the timeframe specified on your product labeling (typically 14-28 days). Label the vial with the reconstitution date. Do not use if the solution appears cloudy, discolored, or contains particles.
Signs of degradation
Sample daily schedule
05 · Safety
Is it safe?
3 common side effects · 2 serious
FDA-approved pramlintide demonstrates good tolerability in insulin-treated diabetes with well-characterized safety profile from >20 years clinical use. Gastrointestinal side effects (nausea) occur in 30-50% of initiators but typically resolve within 1-3 weeks. Hypoglycemia risk, especially when combined with insulin, requires dose coordination and patient education. Pancreatic side effects theoretically possible but not documented in clinical trials. Pregnancy category C requires careful consideration.
FDA approval supported by diabetes randomized trials (n=1000+) demonstrating HbA1c reductions of 0.5-1.0% with weight loss of 1-2 kg over 6 months. Mechanistic studies via stable-isotope glucose tracer methodology show slowed gastric emptying (50-60% reduction in gastric output rate) and inhibited glucagon secretion. Postprandial glucose improvements measured at 2-3 hours post-meal with 40-50 mg/dL average reductions versus placebo.
Common side effects · experienced by some users
Less common
These typically resolve with continued use or dose adjustment.
Stop and seek help if
- ×Severe or worsening side effects that don't improve with dose adjustment or supportive care
- ×Signs of an allergic reaction—rash, hives, swelling, or difficulty breathing
- ×Your healthcare provider recommends discontinuation based on your clinical response
- ×Development of any new medical condition that may be contraindicated with Pramlintide
- ×Pregnancy or planning to become pregnant (unless specifically approved for use during pregnancy)
- ×Abnormal lab results or clinical markers that suggest adverse effects
Pramlintide should only be started, adjusted, or discontinued under medical supervision. This information is for educational purposes only and does not replace professional medical advice. Never stop a prescribed treatment without consulting your healthcare provider first, as abrupt discontinuation may have consequences.
With other peptides
- ✓Insulin (Rapid-Acting) — Essential co-administration — pramlintide is only indicated for use alongside mealtime insulin. Reduces required insulin dose while improving postprandial control.
- ✓Insulin Glargine — Basal insulin provides fasting glucose coverage while pramlintide addresses postprandial glucose spikes and insulin dose optimization
- ✓Metformin — In type 2 diabetes, metformin's insulin-sensitizing action complements pramlintide's postprandial glucose control and weight benefit
With medications
- !Sulfonylureas — Increased risk of severe hypoglycemia due to non-glucose-dependent insulin secretion combined with pramlintide's glucose-lowering effects
- !Alpha-Glucosidase Inhibitors — Both agents slow gastric emptying and nutrient absorption, potentially leading to excessive GI side effects and unpredictable glucose patterns
- !GLP-1 Receptor Agonists — Overlapping mechanisms of gastric emptying delay and appetite suppression with increased GI side effects and hypoglycemia risk
With supplements
- ✓Multivitamins — Generally safe to take alongside Pramlintide. Space doses apart if taking oral formulations to ensure optimal absorption.
- ✓Electrolyte supplements — Helpful if experiencing any GI side effects that could lead to dehydration. Safe to combine.
06 · Effectiveness
How do I know it's working?
Strong human trials · first signs weeks 1-2
Evidence level
Strong human trials
(Phase 3 or FDA approved)
How it works
Pramlintide is a synthetic copy of amylin, a hormone your pancreas naturally makes alongside insulin. It slows down how fast food leaves your stomach, tells your brain when you're full, and stops your liver from releasing too much glucose after meals. Think of it as a helper hormone that works with insulin to keep blood sugar steady and help you lose weight.
Pramlintide is a 37-amino acid synthetic amylin analog (Pro25, Pro28, Pro29-substituted human amylin) that acts as a selective amylin receptor agonist, activating amylin receptor 1 (AmyR1)—a heteromeric receptor complex composed of calcitonin receptor (CALCR) and receptor activity-modifying protein 1 (RAMP1). At peripheral sites, amylin receptor activation on vagal afferents suppresses postprandial glucagon secretion through a glucose-dependent mechanism and delays gastric emptying via direct effects on gastric smooth muscle innervation, both reducing postprandial glucose excursions. Centrally, amylin receptors in the hypothalamus (particularly in the ventromedial hypothalamus and amygdala) mediate appetite suppression and promote satiety signaling, contributing to reduced food intake and weight loss. Unlike insulin (which is glucose-independent and can cause hypoglycemia), amylin's glucagon suppression only occurs when blood glucose is elevated, providing inherent hypoglycemia protection. Pramlintide also enhances energy expenditure through central mechanisms and may have neuroprotective effects, with emerging evidence suggesting amylin may play a role in preventing cognitive decline associated with diabetes.
What to expect
Weeks 1-2
What you might notice
- •Reduced postprandial glucose spikes, possible nausea, reduced appetite
- •Blood glucose may be lower than expected — monitor closely due to 50% insulin dose reduction
What's normal
- •Nausea is very common and expected
- •Blood glucose patterns will change significantly
- •You may feel less hungry after meals
- •Some patients notice flatter post-meal glucose curves within the first few days
What's next
- →Continue at starting dose
- →Begin gradual insulin retitration based on blood glucose data
- →If nausea resolves, prepare for dose escalation as tolerated
Weeks 3-8
What you might notice
- •Improving postprandial glucose control, diminishing nausea, early weight stabilization or loss, ability to titrate to maintenance dose
What's normal
- •Nausea typically resolves by week 3-4
- •Appetite suppression continues but becomes manageable
- •Insulin doses are gradually being retitrated upward toward optimal glycemic targets
- •Weight may begin to decrease
What's next
- →Achieve and maintain target maintenance dose (120 mcg T2DM or 60 mcg T1DM per meal)
- →Fine-tune insulin dosing based on blood glucose patterns
Weeks 12-24
What you might notice
- •Stable glycemic control with reduced HbA1c, sustained weight loss of 1-2 kg, reduced overall insulin requirements compared to baseline
What's normal
- •HbA1c reduction of 0
- •6% is typical
- •Weight loss plateaus at 1-2 kg
- •Postprandial glucose excursions are significantly reduced
- •Mealtime insulin doses are typically 10-30% lower than pre-pramlintide levels after retitration
What's next
- →Continue maintenance therapy with ongoing blood glucose monitoring
- →Reassess HbA1c every 3 months
- →Adjust insulin as needed for sustained optimal control
Signs it's working · Treatment Response
- ✓Improvement in the primary symptoms or condition being treated
- ✓Positive changes in relevant lab values or clinical markers
- ✓Consistent, stable response to Pramlintide over time
- ✓Reduction in symptom frequency or severity
Signs it's working · General Well-being
- ✓Improved energy levels and daily functioning
- ✓Better quality of life related to the treated condition
- ✓Manageable or absent side effects indicating good tolerance
- ✓Positive feedback from healthcare provider during check-ups
Not seeing results? Common reasons
- •Not at therapeutic dose yet—initial doses are for building tolerance, not maximum effect
- •Insufficient time at target dose—most compounds need several weeks to show full benefits
- •Inconsistent dosing schedule—regular, consistent use is crucial for optimal results
- •Individual variation in response—genetics, metabolism, and other factors affect outcomes
- •Underlying conditions or medications interfering with absorption or effectiveness
- •Improper storage leading to degraded product—always verify proper storage conditions
Key research
07 · Questions
Frequently asked
Why does pramlintide have a BLACK BOX WARNING?+
Pramlintide carries an FDA BLACK BOX WARNING for severe hypoglycemia because it is always used in combination with insulin. The combined glucose-lowering effects can cause dangerous drops in blood sugar, particularly during the first weeks of therapy. To mitigate this risk, the FDA mandates that mealtime insulin doses be reduced by 50% when starting pramlintide. Close blood glucose monitoring is essential, and patients must have rapid-acting glucose available at all times.
What is amylin and why is pramlintide needed?+
Amylin (islet amyloid polypeptide) is a hormone naturally co-secreted with insulin by pancreatic beta cells after meals. It plays a crucial role in glucose regulation by suppressing glucagon, slowing gastric emptying, and promoting satiety. In type 1 diabetes, amylin is completely absent due to beta cell destruction. In advanced type 2 diabetes, amylin secretion is severely impaired. Pramlintide replaces this missing hormone, restoring a key component of normal glucose homeostasis that insulin alone cannot address.
Can pramlintide be mixed with insulin in the same syringe?+
No, pramlintide must never be mixed with any type of insulin. The pH of pramlintide solution is different from insulin formulations, and mixing can alter the pharmacokinetics of both drugs. Pramlintide and insulin must be administered as separate injections at separate injection sites, at least 2 inches apart.
Why were proline substitutions made to create pramlintide from native amylin?+
Native human amylin has a strong tendency to self-aggregate and form amyloid fibrils (the same fibrils found in pancreatic islet amyloid deposits in type 2 diabetes). This aggregation makes native amylin pharmaceutically unstable and unsuitable as a drug. The three proline substitutions at positions 25, 28, and 29 were based on rat amylin, which naturally contains prolines at these positions and does not aggregate. These substitutions disrupt the beta-sheet formation that drives amyloid aggregation while preserving full biological activity at amylin receptors.
Is pramlintide suitable for all patients with diabetes?+
No. Pramlintide is specifically indicated for patients with type 1 or type 2 diabetes who are already on mealtime insulin therapy and have not achieved adequate postprandial glucose control. It is contraindicated in patients with gastroparesis, hypoglycemia unawareness, and those who cannot reliably comply with the critical insulin dose reduction requirements. It is not a standalone therapy and is not appropriate for patients not using insulin.
How does pramlintide differ from GLP-1 receptor agonists?+
While both pramlintide and GLP-1 receptor agonists slow gastric emptying and promote satiety, they work through entirely different receptor systems. Pramlintide activates amylin receptors (AMY1/2/3), while GLP-1 RAs activate the GLP-1 receptor. Key differences include: pramlintide must be given with insulin (adjunctive only), GLP-1 RAs can be used independently; pramlintide suppresses glucagon via amylin receptors, GLP-1 RAs stimulate glucose-dependent insulin secretion; pramlintide has a very short half-life (~48 min) requiring injection before each meal, while most modern GLP-1 RAs are once-weekly.
08 · Further reading
History & related research
History · since 1987
The Missing Half of Insulin's Story
From a forgotten hormone hiding in pancreatic deposits to the only FDA-approved amylin replacement — follow the quest to understand why insulin alone wasn't enough, why human amylin is toxic, and how borrowing a rat's chemistry solved a 40-year-old mystery.
Read the full history of Pramlintide